Barclays PLC Has $147,000 Stock Position in Lifecore Biomedical, Inc. (NASDAQ:LFCR)

Barclays PLC increased its position in Lifecore Biomedical, Inc. (NASDAQ:LFCR) by 301.7% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 29,944 shares of the company’s stock after purchasing an additional 22,489 shares during the quarter. Barclays PLC owned approximately 0.08% of Lifecore Biomedical worth $147,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Legion Partners Asset Management LLC raised its holdings in Lifecore Biomedical by 0.6% in the 2nd quarter. Legion Partners Asset Management LLC now owns 2,968,409 shares of the company’s stock valued at $15,228,000 after acquiring an additional 18,182 shares during the period. State Street Corp grew its stake in shares of Lifecore Biomedical by 10.2% in the third quarter. State Street Corp now owns 334,360 shares of the company’s stock valued at $1,648,000 after acquiring an additional 30,916 shares in the last quarter. Marshall Wace LLP raised its stake in Lifecore Biomedical by 87.3% in the 2nd quarter. Marshall Wace LLP now owns 300,120 shares of the company’s stock worth $1,540,000 after purchasing an additional 139,887 shares in the last quarter. DCF Advisers LLC boosted its holdings in Lifecore Biomedical by 2.1% in the 2nd quarter. DCF Advisers LLC now owns 290,684 shares of the company’s stock valued at $1,491,000 after purchasing an additional 6,000 shares during the period. Finally, Bank of New York Mellon Corp acquired a new position in shares of Lifecore Biomedical during the 2nd quarter worth approximately $327,000. Institutional investors own 83.36% of the company’s stock.

Lifecore Biomedical Stock Performance

Shares of Lifecore Biomedical stock opened at $5.91 on Wednesday. The company has a current ratio of 1.83, a quick ratio of 0.80 and a debt-to-equity ratio of 12.90. The company has a market cap of $217.65 million, a PE ratio of 73.88 and a beta of 0.98. The company has a 50 day moving average of $7.05 and a 200-day moving average of $5.82. Lifecore Biomedical, Inc. has a 1-year low of $3.68 and a 1-year high of $8.90.

Lifecore Biomedical (NASDAQ:LFCR) last released its earnings results on Thursday, January 2nd. The company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.02. Lifecore Biomedical had a negative return on equity of 382.65% and a net margin of 5.09%. As a group, equities research analysts forecast that Lifecore Biomedical, Inc. will post -0.99 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the company. Stephens reissued an “equal weight” rating and set a $6.00 price target on shares of Lifecore Biomedical in a research report on Friday, January 3rd. Craig Hallum increased their target price on Lifecore Biomedical from $8.00 to $10.00 and gave the stock a “buy” rating in a report on Friday, November 22nd.

Lifecore Biomedical Profile

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.